Research & Development. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff

Transcription

1 Department Title of SOP Research & Development Safety reporting SOP SOP reference no: R&D GCP SOP 07 Authors: Current version number and date: J H Pacynko and J Illingworth Version 9, Next review date: Target audience: Distribution: Research, pharmacy and R&D staff HEY R&D internet Click on GCP SOPs for HEY-sponsored CTIMPs When this document is viewed as a paper copy, the reader is responsible for checking that it is the most recent version. Hull And East Yorkshire Hospitals NHS Trust 20 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any mean without the prior permission of Hull and East Yorkshire Hospitals NHS Trust R&D department. Authorized by Sign Date R&D Director R&D Manager Professor Anthony Maraveyas James Illingworth Page 1 of 12

2 This page details the version history and the main changes made for each new version. Version Log Version number and date Author Details of significant changes Version 1, 27.. J Pacynko First SOP approved by R&D Committee on 27.. Version 2, J Pacynko Unnecessary wording removed from page 6 line 8. Version 3, J Pacynko Change of SSAR to SAR to be in-line with NIHR GCP training. Contacts with study patients that fall pregnant should be monthly. Version 4, J Pacynko Front cover - SOP available on HEY R&D internet. Internet links updated. Who should use SOP updated. Links and appendices updated. Mention of monthly monitoring under investigator trend analysis. Version 5, J Pacynko Appendix 2 Instructions for processing SAE reports up-dated. Version 6, J Pacynko Checking and up-dating all links Page 6 - Addition of electronic Medicines Compendium link Page 8 - Pregnancy section has been amended to include partners of patients in a clinical trial. Page 8 Addition of a section on the IMP and reference to the IMP recall SOP Appendix 2 Instructions for processing SAE, SAR & SUSAR report forms, up-dated. Version 7, J Pacynko Main changes are in red font. Checking and up-dating all links. Page 7 - Removal of 5 day timeline for reporting of additional information on serious events to R&D. Pages 5, 8, 13 & 14 - Information regarding reporting of patient safety incidents has been up-dated. Version 8, J Pacynko Renaming of serious event initial and follow-up report forms to SAE initial and follow-up report forms. Sponsor (HEY R&D) together with PI to notify REC of esusar reports. Previously this task was delegated to the PI. Page 2 of 12

3 Removal of notifying REC of SAE reports of the death of a trial patient where the death is not related to the IMP as assessed by the PI, as these reports are not required by REC. Added that scanned SAE reports to be ed to R&D Office at research.development@hey.nhs.uk Version Log continued Version 9, S Moffat J Pacynko Pages 7, 8 and Information regarding the use of SPCs for assessing expectedness has been updated to reflect the MHRA requirements. Page 8 - addition of assessments of adverse events table. Checking and updating hyperlinks. Removal of Appendices. Section no. Contents Page no. 1 Introduction 4 2 Purpose and who should use this SOP 4 3 Acronyms and Definitions 5 4 Investigator responsibilities 4.1 All adverse events (non-serious and serious) 4.2 Reporting all serious adverse events (SAE/SAR/SUSAR) SAE initial report form Assessment of adverse events SAE follow-up report form 4.3 Reporting SUSARs Timelines Reporting to the MHRA Reporting to the Research Ethics Committee (REC) 4.4 Code break 4.5 Pregnancy during trial period 4.6 Safety findings flagged by DMC 4.7 Annual safety reporting 4.8 HEY-sponsored multi-site trials and safety notifications 4.9 Patient safety incident reporting 4. Concerns with Investigational Medicinal Product 5 Sponsor responsibilities 5.1 Prior to start of study 5.2 At monitoring visits 5.3 Processing SAE initial and follow-up report forms Page 3 of 12

4 5.4 Trend analysis 11 6 Implementation of this SOP 11 Please note for definitions of acronyms refer to Appendix 1 of Management of SOPs. Refer to Appendix 3 of Management of SOPs for the standards to which clinical trials that investigate the safety and/or efficacy of a medicinal product are conducted. All the R&D GCP SOPs are available at: 1 Introduction The requirements for safety reporting can be found in Part 5 (Pharmacovigilance Regulations 32, 33, 34 and 35) of the Medicines for Human Use (Clinical Trials) Regulations 2004: SI 2004/31 These regulations specify the reporting requirements for research related adverse events. Compliance with these requirements helps ensure the safety of clinical trial subjects. It is a legal requirement for HEY-sponsored trials involving IMPs to comply with the safety reporting procedures specified in this SOP. When the MHRA inspect clinical trials, the GCP inspectors focus on the compliance of investigators, sponsor and monitor with these safety requirements. Within this SOP, the requirements have been transcribed into investigator and sponsor responsibilities. 2 Purpose and who should use this SOP The purpose of this SOP is to describe the responsibilities of investigators and sponsor when reporting serious and non-serious adverse events to ensure compliance with the UK clinical trials regulations. This SOP should be used by: Page 4 of 12

5 o o o o All research staff involved with HEY-sponsored CTIMPs Chief/Principal Investigator, co-investigators, research nurses, clinical trial assistants, project managers, clinical trial co-ordinators, data managers, administrators etc. Clinical trials pharmacy staff technicians and pharmacists. All HEY R&D staff who manage the sponsorship of HEY-sponsored CTIMPs. Research staff involved with clinical trials sponsored by an external organisation where the sponsor has no SOP for safety reporting. HEY R&D SOPs are defaulted to in this case. 3 Acronyms and Definitions AE - Adverse event: any untoward medical occurrence in a clinical trial subject administered a medicinal product which may or may not be caused by or related to that product. Adverse reaction or adverse drug reaction (ADR): any untoward and unintended response in a subject to an investigational medicinal product which is related to any dose administered to that subject. Unexpected adverse reaction: an adverse reaction the nature and severity of which is not consistent with the information about the medicinal product in question set out: (a) in the case of a product with a marketing authorization, in the summary of product characteristics (SPC) for that product (b) in the case of any other investigational medicinal product, in the investigator's brochure (IB) relating to the trial in question. SAE - Serious adverse event or serious adverse reaction: any adverse event, adverse reaction or unexpected adverse reaction, respectively, that: (a) results in death (b) is life-threatening (c) requires hospitalisation or prolongation of existing hospitalisation (d) results in persistent or significant disability or incapacity (e) consists of a congenital anomaly or birth defect. Important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed in the definition above should also be considered serious. SAR - Serious adverse reaction is a serious adverse event that is either possibly, probably or definitely related to the investigational medicinal product. Page 5 of 12

6 SUSAR Suspected unexpected serious adverse reaction is an SAR which is unexpected, meaning that its nature and severity are not consistent with the information about the medicinal product in question set out: (a) in the case of a product with a marketing authorisation, in the MHRA approved summary of product characteristics (SPC) for that product. (b) in the case of any other investigational medicinal product, in the MHRA approved investigator s brochure (IB) relating to the trial in question. An SAE becomes a SUSAR if the event is suspected (possibly, probably or definitely) to be related to the IMP and unexpected i.e. not previously documented in any of the product information (SPC, IB, patient information leaflet) or protocol. Further guidance on safety reporting can be found in: Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (CT-3) June Incidents: An SAE, SAR or SUSAR may also require reporting on a HEY Datix Incident Report Form. For definitions of patient safety incidents that require reporting refer to the Incident Reporting Policy CP Investigator responsibilities 4.1 All adverse events (non-serious and serious) Document all adverse events on the Adverse Events (AE) Log at the back of the trial CRF. The R&D monitor will provide investigators with an electronic AE Log template at study set up in case extra space is needed. Record relevant details of the adverse event in the patient s casenotes. Enter a description of the adverse event, the start and stop date/time and any action taken. Confirm in the casenotes all tests and procedures performed, and who did what and when. Record any follow-up information of the event in the patient s casenotes. All adverse events (serious and non-serious) should be assessed for trends in nature and frequency on an ongoing basis from the start to the end of the trial. Any trends should be reported immediately to the R&D monitor, QA manager, R&D manager or director and will be reported to the MHRA and Research Ethics Committee (REC). 4.2 Reporting all serious adverse events (SAE/SAR/SUSAR) SAE initial report form As soon as possible and within 24 hours of becoming aware of a serious adverse event, complete the SAE initial report form. It is important to respect this timeline since the MHRA closely inspect the reporting of SAEs. Page 6 of 12

7 The R&D monitor will provide investigators with a study specific SAE form template at study set up. Complete the form electronically and as fully as possible with the information available at the time. Definitions of intensity, causality, expectedness and seriousness are listed below. A study medic must complete these sections. Assessment of adverse events The study medic will need to decide whether the serious event is an SAE, SAR or SUSAR by assessing whether the event is related to the IMP (causality) and expected or not. In order to assess expectedness, the study medic will need to check if the event is listed under Undesirable Effects in the MHRA approved Summary of Product Characteristics or Investigator Brochure for the IMP. Intensity The assessment of intensity will be based on the investigator s clinical judgement using the following definitions: Mild: An event that is easily tolerated by the patient, causing minimal discomfort and not interfering with everyday activities. Moderate: An event that is sufficiently discomforting to interfere with normal everyday activities. Severe: An event that prevents normal everyday activities. Comment: The term severity is often used to describe the intensity of a specific event. This is not the same as seriousness which is based on patient/event outcome or action criteria. Causality The relationship between the drug and the occurrence of each adverse event will be assessed and categorised as below. The investigator will use clinical judgement to determine the relationship. Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors etc. will be considered. The Investigator will also consult the Summary of Product Characteristics, Investigator Brochure or other product information. Not related: Temporal relationship of the onset of the event, relative to administration of the product, is not reasonable or another cause by itself explain the occurrence of the event. Unlikely: Temporal relationship of the onset of the event, relative to administration of the product, is likely to have another cause which can by itself explain the occurrence of the event. *Possibly related: Temporal relationship of the onset of the event, relative to administration of the product, is reasonable but the event could have been due to another, equally likely cause. *Probably related: Temporal relationship of the onset of the event, relative to administration of the product, is reasonable and the event is more likely explained by the product than any other cause. *Definitely related: Temporal relationship of the onset of the event, relative to Page 7 of 12

8 administration of the product, is reasonable and there is no other cause to explain the event, or a re-challenge (if feasible) is positive. *Where an event is assessed as possibly, probably or definitely related - the event is an adverse reaction. Expectedness Adverse reactions must be considered as unexpected if they add significant information on the specificity or severity of an expected adverse reaction. The expectedness of an adverse reaction shall be determined according to the reference documents as defined in the study protocol (e.g Summary of Product Characteristics). Expected: Reaction previously identified and described in protocol and/or reference documents e.g. summary of product characteristics (SPC), Investigator Brochure (IB). Unexpected: Reaction not previously described in the protocol or reference documents. NB The protocol must identify the reference documentation used. Seriousness An event is considered serious if it meets one or more of the following criteria: (a) results in death (b) is life-threatening (c) requires hospitalisation or prolongation of existing hospitalisation (d) results in persistent or significant disability or incapacity (e) consists of a congenital anomaly or birth defect. Important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the outcomes listed in the definition above should also be considered serious. The MHRA approved Summary of Products Characteristics (SPC) or Investigator Brochure (IB) is the SPC or IB that was first submitted to the MHRA for clinical trial authorisation. In the event of the SPC or IB being updated, the CI/PI, Sponsor and Pharma Company (if IB) will risk assess the changes and decide if they have an impact on patient safety. If the decision is that the updated SPC/IB needs to be used as the new Reference Safety Information (RSI) then this must be submitted to the MHRA as a substantial amendment. The updated SPC/IB can then be used once approved by the MHRA. Either a scanned copy of the SAE form to the R&D office at research.development@hey.nhs.uk or fax ( ) a copy to the R&D office. Telephone the R&D office ( ) to alert R&D that the or fax has been sent. File the original signed SAE form in the safety section of the Investigator Site File. The Principal Investigator is required to confirm the contents of the report are accurate and complete and that he/she has also assessed the seriousness, intensity, causality and expectedness of the SAE. Page 8 of 12

9 If the trial is multi-centre, the Chief Investigator is required to confirm that he/she has reviewed the report. During R&D s review of the event, downgrading of an event is not permissible and the CI/PI s decision on causality and expectedness will not be overruled. Any additional information as deemed necessary by the sponsor (R&D) will be submitted to the MHRA and REC in a covering letter. SAE follow-up report form As soon as further information becomes available, complete the SAE follow-up form. If the SAE has involved the hospitalization of a patient, then a follow-up form should be completed on discharge of the patient. The R&D monitor will provide investigators with an electronic study specific follow-up form template at study set up. Either a scanned copy of the SAE form to the R&D office at research.development@hey.nhs.uk or fax ( ) a copy to the R&D office. Telephone the R&D office on to alert R&D that the or fax has been sent. File the original signed form in the safety section of the Investigator Site File. Use additional follow-up forms for extra data until the SAE has resolved or a decision has been made for no further follow-up. Send forms to R&D via or fax as above. 4.3 Reporting SUSARs Expedited reports of SUSARs must be sent to the MHRA and REC. The timelines and procedure for reporting SUSARs are detailed below. Timelines For SUSARs the following reporting timelines need to be respected: A SUSAR which is fatal or life-threatening must be reported to the MHRA and REC as soon as possible and no later than 7 days after learning of the event. Any additional information must be reported within 8 days of sending the first report. A SUSAR which is not fatal or life-threatening must be reported to the MHRA and REC as soon as possible and no later than 15 days after learning of the event. Reporting to the MHRA The MHRA require SUSARs to be reported to them electronically via the following website: The R&D monitor/qa manager will contact the reporting investigator to take him/her through the esusar reporting procedure. Page 9 of 12

10 The investigator will be required to complete the esusar report (Stages 1 5) since the additional information requested is only available in patients casenotes. The investigator will need to alert the monitor when the esusar report is complete and saved. The report will be reviewed by the R&D Director and then will be submitted. Reporting to the Research Ethics Committee (REC) R&D will make sure that the same esusar report that has been submitted to the MHRA is also sent to the REC. When submitting the esusar, the following cover form will be used. Form entitled CTIMPs safety report to REC available at: Code break For double-blind trials, on rare occasions, the blind for the study patient may need to be broken to establish the best course of treatment for the patient or to establish whether a serious event is a SUSAR. The investigator should follow the code break procedure set-up and tested for the trial. Clinical trials pharmacy s CT016 code break SOP will be followed. 4.5 Pregnancy during trial period If a study patient, or the partner of a study patient, falls pregnant when participating in a clinical trial, the study patient should be withdrawn from the trial unless the Chief/Principal Investigator decides that the risk to the patient is not clinically significant. The patient, or the partner of the study patient, should be followed up by monthly or two monthly visits/telephone contacts during pregnancy and at birth and at 3 months after the birth of the baby. Whether the visits are every month or two months will depend on clinical judgement and will be agreed with R&D and documented in the TMF. Should there be a congenital anomaly or birth defect, then report as an SAE/SAR/SUSAR as above. 4.6 Safety findings flagged by DMC Any significant findings and recommendations raised by an independent data monitoring committee or equivalent body established for the trial must be reported to the MHRA and REC. 4.7 Annual safety reporting Annual Development Update Safety Reports (DSURs) must be provided to the MHRA and REC. The process for reporting DSURs is given in the Annual Reporting SOP. 4.8 HEY-sponsored multi-site trials and safety notifications Page of 12

11 In multi-site trials where HEY is the lead site, the Chief Investigator must inform all sites rapidly of emerging safety issues, such as the occurrence of SUSARs. Receipts must be obtained from Principal Investigators confirming that they have read safety notifications. 4.9 Patient safety incident reporting If the SAE also comes under the definition of a patient safety incident then report electronically on the Datix Incident Reporting form and submit to the Risk Management Department at HRI. For definitions of patient safety incidents that require reporting refer to the HEY Incident Reporting Policy CP379. For the Datix form click on the Report an Incident icon on the HEY Intranet Homepage. 4. Concerns with Investigational Medicinal Product The investigator team must alert R&D straight away of any concerns regarding the IMP, this may be to do with the expiry of the IMP or the reaction of patients to the IMP or other concerns. R&D will inform pharmacy and with pharmacy and the CI/PI will decide whether it is appropriate to trigger the IMP recall SOP. 5 Sponsor responsibilities 5.1 Prior to start of study The R&D monitor will produce a Reference Safety Information file note explaining the MHRA approved SPCs or IB must be used as the expectedness reference document. The file note will be signed by the research team and will be filed in the safety section of the Investigator Site File together with print outs of the approved SPCs. The MHRA approved SPCs will be reviewed for updates annually at the time the DSUR is completed. 5.2 At monitoring visits Check that all AEs (serious and non-serious) have been recorded on the CRF adverse event report form. Check that SAEs have been reported within the time limits. Check all clinically significant laboratory abnormalities have been recorded as AEs. Check that relevant details about AEs have been entered in the patients casenotes. 5.3 Processing SAE initial and follow-up report forms The R&D office will use Working Instruction 02 for processing SAE report forms. This is saved on the Y drive in Y:\Research\GCP SOPs & forms\working instructions. These instructions are regularly up-dated. R&D to process SAE reports within 24hrs of receipt of report. Page 11 of 12

12 If the serious event is a SUSAR, contact the reporting investigator and arrange to go through the esusar reporting procedure either in the investigator s department or at R&D. Use the esusar reporting Working Instruction 03 saved in Y:\Research\GCP SOPs & forms\working instructions. Summaries of all serious events from all HEY-sponsored CTIMPs reported to HEY R&D are logged in a CTIMP summary spreadsheet available at Y:\Research\GCP SOPs & forms\saes, SARs & SUSARs\Summary table of serious events\current versions. Serious events are also logged chronologically on EDGE. 5.4 Trend analysis A trend analysis of the SAEs reported to R&D will be performed every 6 months by the R&D director, unless concerns are raised by the investigator or R&D about the number or type of SAEs in a trial in which case the R&D Director will become involved straight away. During the 6-month trend analysis, the R&D Director will assess the nature and frequency of the SAEs for each trial and any trends will be discussed with the investigator and reported to the MHRA and REC. 6 Implementation Implementation of this SOP will conform to the process outlined in R&D SOP 01 Management of SOPs. Page 12 of 12